9/25/2018 8:06:19 AM
Mersana Therapeutics Presents New Preclinical Data On XMT-1536 At IASLC
9/18/2018 6:40:24 AM
Wedbush Reiterates Mersana Therapeutics, Inc. (MRSN) At Outperform With $15 Down From $16 Price Target
9/17/2018 7:03:50 AM
Mersana Therapeutics: FDA Lifts Partial Clinical Hold For XMT-1522
8/14/2018 4:27:13 PM
Mersana Therapeutics Q2 Loss/share $0.54 Vs. Loss $6.33 Year Ago
7/19/2018 8:11:25 AM
Mersana Therapeutics Says FDA Placed Phase 1 Study Of XMT-1522 On Partial Clinical Hold
5/15/2018 7:39:26 AM
Wedbush Is Raising Mersana Therapeutics, Inc. (MRSN) FY18 Rev. Estimate To 13.9 M From 11.0 M
5/15/2018 7:39:14 AM
Wedbush Is Increasing Mersana Therapeutics, Inc. (MRSN) Q4 18 Rev. Estimate To 3.6 M From 2.7 M
5/15/2018 7:39:06 AM
Wedbush Is Raising Mersana Therapeutics, Inc. (MRSN) Q3 18 Rev. Estimate To 3.6 M From 2.7 M
5/15/2018 7:38:57 AM
Wedbush Is Increasing Mersana Therapeutics, Inc. (MRSN) Q2 18 Rev. Estimate To 3.6 M From 2.7 M
5/15/2018 7:38:30 AM
Wedbush Is Raising Mersana Therapeutics, Inc. (MRSN) FY18 Estimate To -2.41 From -3.15
5/15/2018 7:38:12 AM
Wedbush Is Raising Mersana Therapeutics, Inc. (MRSN) Q4 18 Estimate To -0.66 From -0.87
5/15/2018 7:37:59 AM
Wedbush Is Raising Mersana Therapeutics, Inc. (MRSN) Q3 18 Estimate To -0.62 From -0.82
5/15/2018 7:37:31 AM
Wedbush Is Raising Mersana Therapeutics, Inc. (MRSN) Q2 18 Estimate To -0.58 From -0.76
5/14/2018 4:05:44 PM
Mersana Therapeutics Q1 Loss/share $0.54 Vs. Loss $6.02 Year Ago
3/28/2018 1:18:47 PM
Wedbush Is Lowering Mersana Therapeutics, Inc. (MRSN) 2018 Estimate To -3.15 From -2.41
3/28/2018 1:18:35 PM
Wedbush Is Lowering Mersana Therapeutics, Inc. (MRSN) 4Q18 Estimate To -0.87 From -0.67